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NCCN               : National comprehensive cancer network 
EGFR             : Epidermal growth factor receptor 
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COMPARISON OF STROMAL CD10 EXPRESSION IN 
BENIGN, BORDERLINE AND MALIGNANT 
PHYLLODES TUMORS 
ABSTRACT 
BACKGROUND : 
            Phyllodes tumor is a rare fibroepithelial tumor of the breast comprising 
less than 1% of all primary breast tumor. Phyllodes tumors are graded into 
benign, borderline and malignant based on histological criteria. Grading of 
phyllodes tumor is important as it determines the biological behaviour of the 
tumor. 
AIMS: 
  The aim of the present study was to identify the incidence and 
clinicopathological features of benign, borderline and malignant phyllodes 
tumors and to compare the CD10 expression in benign, borderline and 
malignant phyllodes, in order to highlight its diagnostic significance. 
MATERIALS AND METHOD: 
          The clinical and pathological findings of phyllodes tumors were retrieved 
from the surgical pathology records from January 2012 to June 2014.Totally 50 
case were selected randomly  (38 benign, 6  borderline and 6 malignant) and 
their representative formalin fixed paraffin embedded tissue samples were 
subjected to immunohistochemistry for CD10 expression. 
  
RESULTS: 
     In the 38 cases of benign phyllodes tumors, only three cases (7.9%) were 
CD10 positive. Three out of six cases (50%) of borderline phyllodes tumors 
showed CD10 positivity, whereas five out of six cases (83.3%) of malignant 
phyllodes tumor showed CD10 positivity. 
CONCLUSION: 
             CD10 expression correlated well with grade of phyllodes tumors, which 
is of statistical significance and therefore it can be used in the determination of 
tumor grade and this may pave way for development of targeted therapies. 
 
       
1 
 
 
INTRODUCTION 
 
               Phyllodes tumor(PTs) is a rare fibroepithelial neoplasm which was 
characterised fully by Johannes muller in 1838 as cystosarcoma phyllodes.[1] 
Fibroepithelial tumors are named so, as it contains both epithelial and 
mesenchymal component with fibroadenoma being more common and 
phyllodes tumor being rare which are placed at the far end of stromal 
progression. 
 
             Among all primary tumors of breast, phyllodes tumor constitutes        
0.3-1.0% and estimated to account for 2.5% of fibroepithelial tumors of 
breast.[2] Most tumors occur in women aged between 45-49 years.[3] 
 
             Though phyllodes contain both epithelial and stromal component, 
neoplastic component is formed by stroma which determines the behaviour of 
the tumor.[4] 
 
              Based on histological features phyllodes tumors is subclassified into 
benign, low grade malignant  or borderline and malignant phyllodes tumors 
according to the following features 
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 Stromal cellularity, 
 Stromal overgrowth, 
 Tumor margin, 
 Cellular atypia and 
 Number of mitosis per 10 high power field (HPF). 
               
 Benign phyllodes tumor being most common subtype, it accounts for 
35% to 64% with remainder divided between intermediate and malignant 
subtypes.[5] 
 
 Grading of tumor is important as it determines the biological behaviour 
of the tumor with recurrence rate of 8 to 65% depending on grade.[6] Distant 
metastasis of tumor is encountered in up to 22% of malignant tumors[7] 
whereas metastasis is not reported in benign tumor. 
 
 There is interobserver variation in grading phyllodes especially in 
intermediate variant as tumors were more atypical than the benign but does not 
fulfil the criteria of malignancy. Hence, there is a need for a marker for proper 
grading and evaluating its clinical behaviour for proper treatment, as death is 
more common due to metastasis in borderline and malignant subtypes than 
local recurrence. 
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              CD10 known as common acute lymphoblastic leukemia antigen is a 
zinc metalloproteinase which is normally expressed in myoepithelial cells of 
breast. It is commonly used in diagnosis of stromal malignancy especially in 
uterus to differentiate stromal tumors from smooth muscle tumors. Its 
expression in tumors facilitate metastatic potential of tumor with capacity to 
invade blood vessels thus indicating the presence of it commonly in higher 
grade tumors. 
 
              In this study CD10 expression in the stromal cells of benign, 
borderline and malignant phyllodes which are already  histologically classified 
is studied and its role in grading of tumor is evaluated.    
  
 
 
 
 
Aims and Objectives 
 
  
4 
 
 
 
AIMS AND OBJECTIVES 
 
1. To evaluate the incidence of benign, borderline and malignant 
phyllodes. 
 
2. To study the clinical and histopathological features of benign, 
borderline and malignant phyllodes. 
 
3. To study and compare the expression of CD 10 in benign, borderline 
and malignant phyllodes.  
  
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
  
ANATOMY AND MICROANATOMY OF BREAST: 
 Mammary gland is a modified sweat gland which develops from milk 
line or mammary ridges which are epidermal thickening that appears on the 
ventral surface of foetus during 5th week of gestation.[8] It rests over pectoralis 
muscle in the chest wall between second and sixth rib. 
 
 It is covered with skin and subcutaneous tissue and composed of 
epithelium, stromal cells and adipose tissue. 
 
 Mammary gland is composed of 15 to 25 lobes consisting of lactiferous 
duct which dilate to form lactiferous sinuses before terminating in nipple. 
Lactiferous ducts within a lobe divide repeatedly forming segmental, 
subsegmental and terminal duct. 
 
 Terminal duct leads to lobules which consist of multiple acini. These 
terminal ducts along with acini form terminal duct lobular unit.[9] 
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 Entire ductal and lobular units are lined by two layers - luminal cuboidal 
or columnar epithelial cells and outer myoepithelial cells. Entire glandular 
structure is supported by fibrofatty tissue. 
 
Stroma of breast 
 
Intralobular           Interlobular 
 
 Interlobular stroma is composed mainly of dense fibrous connective 
tissue admixed with adipose tissue.[10,11] 
 
 In Intralobular stroma, it is less densely collagenised and contains more 
capillaries. Cells present in the stroma is found to have paracrine effect on the 
epithelium.[12]  
 
 Stroma also contains scattered inflammatory cells like lymphocytes, 
plasma cells, macrophages and mast cells. Ochrocytes  lipofuscin containing 
periductal histiocytes are usually seen in association with proliferative breast 
disease, inflammatory condition and postmenopausal women.[13] 
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 Both epithelium and stroma cells are hormonally responsive which is 
responsible for changes occurring during menstrual cycle, pregnancy and 
lactation. 
 
Fibroepithelial tumor: 
 Fibroepithelial lesions are biphasic lesions composed of both epithelial 
and mesenchymal components in varying proportions. 
 
Tumors included in this category are  
 Fibroadenoma 
 Phyllodes tumor  
 Sclerosing lobular hyperplasia 
 Hamartoma 
 
 Of these fibroadenoma is the commonest having both components and 
phyllodes being rare and are placed at the far end of stromal progression. 
 
Phyllodes tumors: 
 Uncommon fibroepithelial tumor having double layered epithelial 
component forming clefts surrounded by hypercellular stromal component.[2] 
Though it contains both components, neoplastic component is formed by the 
stroma. 
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 The term phyllodes were derived from word ‘phyllos’ in greek meaning 
‘leaf’ as stroma shows leaf like growth pattern that projects into cleft like 
spaces which are lined by epithelium.[14]   
               
 Phyllodes tumor was first described as giant fibroadenoma in the year 
1774.[1]  It was first described by Chelius in the year 1827.[15] Later in 1838 it 
was fully characterised by Johannes Muller who first used the term 
cystosarcoma phyllodes based on its fleshy appearance and leaf like projection 
of stroma.[1] 
 
 It was considered to be benign until Cooper and Ackerman reported 
malignant potential of this tumor in the year 1943.[16] The term phyllodes 
tumor was adopted by WHO in the year 1981. Later it was subclassified based 
on histology into benign, low grade malignant potential (borderline) and 
malignant, with chances of recurrence and metastatic potential increasing with 
grade.  
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Epidemiology: 
 Phyllodes tumor constitute 0.3 to 1.0% of all primary breast tumors and 
accounts for upto 2.5% of fibroepithelial tumors.[2] In a population based study 
conducted in USA there was an annual incidence of 2.1 per million women.[3]  
Asian and latin American whites have increased incidence.[3,17] 
 
 It occurs commonly in women in the age group of 35-55 yrs with mean 
age of 45 years and when compared with fibroadenoma, it occurs 15-20 years 
later. Among Asians it occurs relatively at youger age group. Cases have also 
been reported in adolescents and in elderly women. 
 
 Though very rare, a few cases have been reported in men and it is 
invariably associated with estrogen induced gynecomastia.[18] 
 
 Majority of PTs are benign accounting for 35% to 65% with remainder 
of the cases divided between intermediate and malignant subgroups.[5]  
Although malignant PTs are rare it occurs more frequently in latino whites. 
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Etiology: 
 Phyllodes tumors are thought to arise from periductal or intralobular 
stroma. Exact etiology of PTs are unknown. Nearly 40% of phyllodes tumor 
has coexisting fibroadenoma[19], but its etiological role is unclear. 
 
 According to Noguchi et al.[20] Clonal analysis showed that, in 
fibroadenoma both epithelial and stromal component are polyclonal and 
should be considered hyperplastic rather than neoplastic. Whereas in 
phyllodes, epithelial cells are polyclonal and stromal cells are monoclonal 
suggesting it as a tumor of stromal origin. Since it has both components it has 
been suggested that phyllodes tumor begin as fibroadenoma with somatic 
mutation in stromal cell resulting in evolution of PTs as shown in fig.1. 
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 This hypothesis was supported by a study conducted by Kuijper et al.[21] 
using PCR assay targeted at human androgen receptor gene.  
 
 In 2005 kujiper et al. found that there is an increase in cell cycle 
dysregulation of stromal component as the grade of  phyllodes tumors  
increases.[22]  
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Risk factors: 
 Ethnicity – Higher incidence of phyllodes tumor in asian and latina 
women[3] and it occurs at significantly younger age group in asian 
women. 
 Fibroadenoma 
 Li-fraumeni syndromre, a rare autosomal dominant syndrome 
characterised by multiple tumors are found to be associated with PTs 
also. 
 
Clinical features: 
 Most common presentation is lump breast and they are indistinguishable 
from fibroadenoma.  Usually presents as unilateral solitary mass and most 
commonly occurs in upper outer quadrant with propensity to occur equally in 
both the breasts. Rarely multifocal lesions can occur in same breast[19,23] or 
both breasts.[19,24,25] Rare cases of PTs in vulva[26] or the axilla[27] have been 
reported where it has been arising from ectopic breast tissue. 
 
 Clinically it presents as a well demarcated, fairly mobile, firm to hard 
palpable mass. Size of the tumor ranges from 1-20cm with an average size of   
4-5cm. Larger size and rapid growth suggest PTs rather than fibroadenoma. 
Rapid growth in a pre-existing stable lesion suggests malignant progression. 
Studies show that there is direct relationship between increasing size and 
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malignancy.  But there are exceptions with high grade malignant tumor smaller 
than 2cm and benign tumor being larger. 
 
 Other findings include pain, nipple discharge due to spontaneous tumor 
infarction,  prominent dilated veins over the skin and skin ulceration mainly in 
larger size tumor due to pressure effect rather than invasion. 
                    
Radiological findings:  
 Ultrasonography 
  PTs are ovoid or lobulated, well circumscribed with smooth 
margin with heterogenous  internal echoes.[28] 
 
  Study conducted by Liberman et al. has shown that retrotumor 
acoustic enhancement and hypoechoic internal echoes is present in majority 
of benign as well as malignant phyllodes.[29]  
 
  Though some authors suggest intramural cysts within solid mass 
of breast as characteristic feature of phyllodes tumor[28,29] , such findings  
are also present in other well circumscribed neoplasms of breast, like 
medullary carcinoma which implies that this cannot be considered as 
pathognomic feature. 
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 Color and pulse Doppler ultrasonography 
 As microvessel density is increased in borderline and maligmant 
PTs, various flow indices aid in differentiating benign from malignant. 
Features favouring malignancy are 
 
 Increased pulsatility index (PI), 
 Increased Resistance index (RI), 
 Increased systolic peak flow velocity (Vmax), 
 Marked hypoechogenicity, 
 Ill defined tumor margin , 
 Posterior acoustic shadowing.[30] 
               
 Mammography 
 Shows well circumscribed lobulated or ovoid mass with 
radiolucent halo around the mass. Coarse calcification may be seen 
rarely.[31] 
 
 Magnetic resonance imaging 
 Lobulated mass with well defined margin and heterogeneous 
internal echoes. 
 Hypointense on T1 and  
 ISO/Hyperintense on T2 weighed images. 
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With contrast enhancement - benign and malignant can be 
differentiated. 
 
 Benign tumors - initial slow enhancement with persistence of 
delayed phase. 
 Malignant tumors -  fast initial enhancement with plateau of 
delayed phase.[31,32,33,34] 
 
Macroscopic appearance: 
 Phyllodes tumors are well circumscribed tumor, grow radially 
compressing the adjacent parenchyma forming pseudocapsule with pushing 
margin, whereas margin is infiltrative in malignant PTs. They present as single 
or multinodular mass with lobulated surface. 
 
Cut surface 
- grey to tan bulging mass giving cauliflower like appearance 
- firm and rubbery in consistency sometimes soft with gelatinous areas 
- shows characteristic whorling pattern with cleft like spaces 
- large tumor shows cystic degeneration with area of hemorrhage and 
necrosis. 
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Microscopic appearance: 
Grading: 
 Many grading system have been proposed that divide PTs into either 
two subgroups (benign and malignant) or three (benign, borderline and 
malignant) subgroups. 
        
 World Health Organization (WHO) classified phyllodes tumor into 
benign, borderline and malignant tumors based on the following histological 
features. 
 Stromal cellularity  
 Stromal overgrowth  
 Cellular atypia 
 Mitosis per 10 high power field (HPF) 
 Tumor margin. 
 
Cytology: 
 FNAC in the diagnosis of phyllodes tumors has limitations, with 
diagnostic accuracy of about  63%.[35] 
 
 As both epithelial and stromal components are present in both 
fibroadenoma and PTs, it is difficult to differentiate them cytologically rather 
than differentiating benign from malignant phyllodes tumors. 
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Features favouring diagnosis of PTs are 
 Hypercellular cohesive stromal fragments 
 Well delineation of fragment borders 
 Bipolar naked nuclei 
 Stromal nuclear atypia 
 Blood vessels crossing stromal fragments 
 Tumor giant cells and absence of apocrine metaplasia.  
 
 Deen et al.[36] and Jayaram and Sthaneshwar[37] classified cells on smear 
by comparing it with small lymphocytes as 
 
Epithelial cells  - small, round to oval with size two times smaller than  
    size of lymphocyte 
Stromal cells     - long spindle cell, three times larger than size of  
    Lymphocyte 
Benign PTs  - stromal fragment, singly dispersed stromal cells,  
             naked stromal nuclei which are more numerous than  
    epithelial cells. 
Borderline PTs -  stromal cell predominant with atleast two fragment  
    in each field, large stromal cells and  monomorphic  
    naked nuclei. 
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 Malignant PTs - cellular smear, stromal fragments with discohesive 
spindle cells, bizarre multinucleate giant cells and minimal or absent epithelial 
element. 
 
Biopsy: 
 Core biopsy is preferred over FNAC as it provide architectural 
information and has a sensitivity of 99%, with 83% and 93% of positive and 
negative predictive value.[38] 
 
 Paddington clinicopathological suspicion score[39]-Criteria outlined  in 
this help to identify patients for core biopsy in order to improve preoperative 
diagnosis. 
 
Paddington clinicopathological suspicion score- 
 
Clinical findings 
i) Sudden increase in size in a longstanding breast lesion 
ii) Apparent fibroadenoma > 3cm diameter or in patient >35 years 
 
Imaging findings 
i) Rounded borders/lobulated appearance at mammography 
ii) Attenuation or cystic areas within a solid mass on Ultrasonography 
19 
 
 
FNAC findings 
i) Presence of hypercellular stromal fragments 
 ii) Indeterminate features. 
 ANY 2 features mandate core biopsy. 
 
 Stromal features that has to be seen in core biopsy include  nuclear 
atypia, mitosis, cellularity and amount of stroma  compared to epithelium.[40] 
Of these, mitosis is the most significant feature in differentiating PTs from FA. 
 
          In benign PTs where it lacks nuclear atypia and mitosis prominent 
periductal proliferation of stromal cells, exaggerated intracanalicular growth 
pattern and heterogenous stromal cell help to differentiate it from FA with 
increased cellularity. 
 
 In case if it is not possible to differentiate it from FA in core biopsy, 
lesion should be designated as cellular fibroepithelial lesion to avoid 
underdiagnosis and should be recommend for exicision . 
 
 Grading should be done mainly in exicision biopsy to avoid 
undergrading due to sampling error. Histological criteria for grading into 
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borderline and malignant was described first by pietruszka and Barnes[41] and 
later Azzopardi[42] modified it and it is adopted by WHO. 
 
Benign phyllodes tumor 
 Most common subgroup of phyllodes tumor accounting for 60% arise 
from periductal or inralobular stroma. Similar to fibroadenoma benign PT has 
both epithelial and stromal component but it shows stromal hypercellularity 
resembling exaggerated intracanalicular fibroadenoma with leaf like growth 
pattern of stroma into the cleft like space. 
 
 Epithelial component consists of luminal epithelial and basal 
myoepithelial cells. Epithelial hyperplasia is common and other changes taking 
place include squamous metaplasia and rarely apocrine metaplasia .  
 
 Stromal  density is more and seen in the immediate vicinity of epithelial 
element, so called periductal stroma and these areas show increased mitotic 
activity. Stromal cells show heterogeneity within same lesion and differ from 
case to case. Myxoid stromal change and hyalinisation are more common 
finding and pseudoangiomatous stromal hyperplasia (PASH) are also seen in 
PTs. Rare changes occurring in PTs include lipomatous, cartilaginous and 
osseous metaplasia. Necrosis are usually seen in larger benign tumors.  
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Features to designate tumor as benign include[2] 
 Low stromal cellularity 
 Absent to mild stromal cell atypia 
 Low mitotic count(0-4/10HPF) 
 Minimal stromal overgrowth 
 Well circumscribed pushing margin 
 Rare heterologous stromal element. 
 
It is usually difficult to differentiate it from FA. Features favouring PTs are 
 Stromal hypercellularity 
 Periductal stromal condensation 
 Stromal heterogeneity (stroma is uniform in FA) 
 Cellular atypia and Mitotic figure.   
 
 Benign features of this tumor does not rule out local recurrence as 
recurrence mainly depends on completeness of excision. 
 
Borderline phyllodes tumor 
 Those tumors which histologically shows some features between benign 
and malignant  but does not possess all the features for malignancy comes 
under this category. 
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 This pose a great problem for both clinician and pathologist in  
assessing the likelihood of local recurrence and metastatic malignant potential.   
 
Features favouring borderline PTs are[2] 
 Moderate to marked stromal cellularity 
 Moderate to marked stromal overgrowth 
 Moderate atypia 
 Number of mitosis 5-9/10HPF 
 Pushing or Infiltrative margin. 
                   
 Epithelial hyperplasia is more commonly found than in benign PTs and 
also shows increased microvessel density. 
                      
Malignant phyllodes tumor 
 This forms the other end of the spectrum of phyllodes tumor which 
accounts for about 20%. 
 
Features favouring malignancy include[2] 
 Marked cellularity 
 Marked stromal overgrowth  
 Marked stromal atypia 
 Infiltrative margin 
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 Mitotic rate >10/10HPF 
 Necrosis and hemorrhage 
 Malignant heterologous element 
 
 Most common stromal sarcoma pattern is that of fibrosarcoma. Other 
heterologous differentiation include liposarcoma, chondrosarcoma, 
osteosarcoma, rhabdomyosarcoma and rarely angiosarcoma. Liposarcoma has 
been the  most common among heterologous differentiation with good 
prognosis if completely excised.  
 
 Stromal overgrowth  here will be extensive there by masking epithelial 
component and hence it warrants extensive sampling. 
 
 Some articles suggest a mitotic rate of >5/10HPF as an indicator of 
malignancy, in view of absence of worrying features mitotic rate of 
>10/10HPF would be more significant. 
 
Local recurrence : 
 Both benign and malignant tumors have local recurrence which ranges 
from 10%-40%. Grading has some correlation with local recurrence which 
ranges from 10% to 25% in benign, 32% in borderline and upto 40% for 
malignant PTs.[17] 
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Features favouring local recurrences include 
 Incomplete excision 
 Infiltrative margin 
 Secondary nodule at tumor periphery. 
 Usually local recurrences occur within first three years of surgery, but it 
occurs much earlier in malignant than benign tumors.  
 
 Rather than grading it is more correlated with the extent of primary 
surgery with more recurrence occurring in tumor with positive margin. Though 
size of tumor has no direct role in predicting local recurrence, it does 
determine the extent of surgery and marginal status. 
 
 Recurrent lesion may present as either  biphasic having both  epithelial 
and stromal elements or monophasic with  only stromal component. 
Sometimes stromal cells in recurrent lesion may show increased cellularity  
with aggressive histological features when compared with the  original tumor.    
 
Metastasis : 
 Metastasis are usually seen in borderline and malignant PTs tumors with 
metastatic rate of about 22% have been reported in malignant lesion  and is not 
seen in benign tumors . 
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According to Hawkins et al[43] , features that predict metastasis are; 
 
 Nuclear pleomorphism 
 High mitotic rate >10/10HPF 
 Size >10cm 
 Stromal overgrowth and 
 Necrosis. 
 
 Usually these tumors metazise to distant site. As it spreads through 
hematogenous route, axillary nodes are very rarely involved (<1%).  
 
       Metastases are common in tumor showing chondro[44] or osteosarcoma[45] 
features and rare in tumor  showing liposarcomatous feature.[46] 
 
        Most common sites of metastasis include lung, bone and abdominal 
viscera. Other rare sites like heart and central nervous system have also been 
described. For sites of metastasis, they usually contain the stromal component 
of the neoplasm. Metastasis indicate poor prognosis of tumor. 
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Prognosis and survival rate: 
 Poor prognostic factors include 
           - presence of malignant heterologous element 
          - metastasis (as it is a common cause of death). 
 According to Belkacemi et al[47], 5 and 10 year survival rate was found 
to be 97% and 96%, whereas it was reported to be 79% and 62% by Chaney et 
al.[48]  Overall survival rate for malignant tumors varies from 42% to 95%. 
 
Treatment: 
 Mainstay of treatment for PTs is surgery with adequate margin 
clearance. Depending on size it may be either wide local excision with 1 cm 
margin clearance or mastectomy. 
 
 National comprehensive cancer network (NCCN) has given guildeline 
for management of PTs which is shown below. 
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  Clinical evaluation of phyllodes tumor 
 Palpable mass 
 Growing rapidly 
 Size > 2cm 
Screening test 
 History/examination 
 USG 
 Mammogram (>30 yr) 
                 Excision biopsy 
 
Fibroadenoma       phyllodes                        
                                 Tumors 
 Benign 
 Borderline  
 Malignant 
 
    
Observe           wide excision 
         (≥1cm) 
        Without 
                        axillary staging 
                           
         Core needle biopsy 
 
Fibroadenoma/    phyllodes 
Indeterminate         tumor  
 
 
Excision                    wide           
biopsy                    excision 
                                ( ≥1cm) 
  Without axillary 
          staging 
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 Smaller biopsy may help in deciding the type of surgery based on 
diagnosis. 
 
 Smaller lesions require only WLE with 1-2 cm margin clearance 
whereas larger lesion requires mastectomy. In younger patients who need 
reconstructive surgery partial mastectomy with lattismus dorsi flap have 
shown good results. 
 
 Nowadays breast conserving surgery and WLE are preferred over 
mastectomy. Guillot et al.[49] in a study of 165 patients, 97%  underwent breast 
conserving surgery and only 5% had mastectomy. As lymph node metastasis is 
very rare there is no role for axillary sampling. 
 
 Whatever is the surgery marginal clearance plays an important role in 
preventing local recurrence. According to Barth’s[50] even in malignant PTs 
there is no survival significance based on type of surgery.  
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Management of local recurrence based on NCCN guideline 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
      
             Excision of phyllodes tumor  
               Breast mass recurs locally 
Screening test 
 History/examination 
 USG 
 Mammogram 
 FNAC/ Small Biopsy 
 Chest xray/CT 
                   METASTASIS 
          
 
To follow soft tissue        
sarcoma management 
protocol                  
          NO METASTASIS 
 
Reexcision with wide margin 
without axillary staging 
 
      Post op radiotherapy 
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Radiotherapy  
 
           There is a controversy over the use of radiation therapy and no firm data 
is available to support its use. 
 
             Similar to soft tissue sarcoma, adjuvant radiotherapy (RT) has been 
recommended to prevent local recurrence in malignant PTs. It has also been 
recommended for patients with adverse pathological features like tumor size 
>5cm and positive margin.[51] In a population based study conducted in 821 
patients,  it was found to have worse prognosis compared with patients treated 
with surgery alone.[52] Study conducted by Soumarova et al. showed local 
recurrence of 12% in patient treated with adjuvant radiotherapy compared to 
25% of patients who have not received RT.[53] 
 
          Later in 2009 clinical trial was conducted, were patient with malignant 
PTs were treated with breast conservative surgery and adjuvant RT and 
followed up for 56 months for local recurrence. None showed local recurrence 
thereby concluded that margin negative resection combined with adjuvant RT 
forms effective management in preventing local recurrence in borderline and 
malignant phyllodes.[54] 
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         Currently adjuvant RT is not routinely used and is recommended only 
where margin clearance cannot be achieved, inoperable local recurrence and 
metastatic tumors. 
 
Chemotherapy  
 There is no clear evidence suggesting beneficial role of 
chemotherapy(CT) in treating phyllodes tumors. Some case reports have 
shown a positive response to chemotherapy in metastatic tumors. Guideline for 
CT is same as that of soft tissue sarcoma. Drugs commonly used are 
ifosfamide, doxorubicin, cisplatin and  etoposide.[55,56] 
 
        Adjuvant chemotherapy has no survival significance hence currently 
chemotherapy is not recommended. 
 
Hormonal and biological therapy     
 Estrogen and progesterone receptor expression were assayed  
immunohistochemically and it was found that receptors were expressed in 
glandular epithelium and not expressed in stroma. Therefore it is unlikely that 
these tumors will respond to hormonal therpy.  
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 Recent advancement and understanding of biological marker and its 
expression in phyllodes tumor  (c-kit, EGFR,CD10...)  might provide room for 
application of targeted therapy in the near future. 
 
Role of Biological markers: 
 Many markers have been studied and most were found to have 
correlation with grading but no marker is able to predict recurrence or 
metastasis. 
 
p53 
 Tumor suppressor gene mapped to chromosome 17p13 which regulate 
cell cycle. 
 
 Most commonly studied marker in PTs and its expression increases with 
grade of tumor. It is found to be associated with high mitotic rate, cellular 
atypia and stromal overgrowth. 
 
 Staining pattern - diffuse strong nuclear stain in malignant tumor 
especially in subepithelial and highly cellular area.[57] 
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 Most studies show p53 expression is not associated with outcome, but 
Study conducted by yonemori et al. found that increased expression of p53 
indicate poor prognosis.[58] 
 
ki67 
 This non histone protein is a marker for cellular proliferation. Its 
exression varies from 5%-25% in benign to 15% to 100% in malignant 
tumor.[58,59] Association of increasing expression of this marker with increasing 
grade has been well documented and  some studies suggest it to be a useful 
marker in predicting outcome.[58,59,60] 
 
c-kit (CD117) 
 c-kit, a protooncogene  which is important diagnostic marker for GIST 
encodes tyrosine kinase receptor. Its expression in PTs vary from 5% to 46% 
in benign to 46% to 100% in malignant.[61,62]  Studies shows that, its 
expression is associated with recurrence.[61]  
 
 As its expression is more in higher grade, the role of tyrosine kinase 
inhibitor as treatment for higher grade lesion and recurrence has to be 
explored. 
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Hormone receptors 
 Estrogen α and progesterone receptors were expressed only in epithelial 
component and not seen in stromal component. Recent evidence shows the 
expression of estrogen β in stromal cells[63], but its role in PTs has not been 
established.    
  
Angiogenesis 
 Increase in microvessel density from benign to malignant tumor was 
assessed by using CD31, its role in predicting outcome was not found.  
Tse et al. in his study shows  an association between microvessel density, p53 
expression and stromal cellularity.[64] 
 
EGFR 
        Like other biological markers, EGFR expression also increases with 
increasing grade of tumor ranging from 12% to 16% in benign to 56% to 63% 
in malignant tumors, but its mechanism for overexpression remains unclear. 
 
             While egfr gene amplification was found only in 8-16% by FISH, the 
likely mechanism for its overexpression may include gene polysomy or 
activating mutation. 
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IMMUNOHISTOCHEMISTRY(IHC) 
 Albert coons et al. in 1941 first described this molecular technique. 
Principle  of this technique is to identify antigen  in cell by antigen antibody 
interaction. Original method consist of developing an antibody against an 
antigen in rabbit and then it is tagged with fluorescent dye isocyanate. when it 
binds to antigen in tissue it emit apple green fluorescence which is detected by 
fluorescent microscope, one of the limitation of this method which is 
overcome by the use of enzymes as labels.[65] 
 
 Since then numerous advancement has been made in the field of 
immunohistochemistry. Nakane and Pierce et al. in 1966, introduced the 
indirect labelling technique in which the unlabelled antibody is followed by 
second antibody or substrate. Most commonly used techniques include 
Peroxidise antiperoxidase technique described by Sternberger et al. (1970) and 
Biotin avidin technique described by Heggeness and Ash in 1977.[66,67] 
 
ANTIGEN RETRIEVAL:  
 Antigen has to be retrieved as it is masked during formalin fixation and 
paraffin processing. 
  
36 
 
 
Antigen retrieval can be done by any one of the following techniques  
1. Proteolytic enzyme digestion 
2. Heat mediated antigen retrieval which include; 
Microwave antigen retrieval 
Pressure cooker 
Steamer 
Water bath and 
Autoclave  
 
PROTEOLYTIC ENZYME DIGESTION:[68] 
 Huang et al in 1976 introduced this technique to breakdown formalin 
cross linkages and to unmask the antigen determinants. The most commonly 
used enzymes include trypsin and protease. Others that can also be used are 
proteinase K, chymotrypsin and pepsin. The disadvantages include over 
digestion, under digestion and antigen destruction. Therefore the optimal 
concentration of enzyme and incubation time needs to be validated. Advent of 
heat retrieval technique replaced this method. 
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HEAT INDUCED EPITOPE RETRIEVAL 
Here the tissue sections are placed in the retrieval solution and heat is 
applied for varying period of time. This result in breakdown of protein cross-
links formed by formalin fixation and recovers the tissue antigenicity. [69] 
 
 Commonly used retrieval solution is the Citrate buffer with pH 6.0. 
Other retrieval solutions include the TRIS-EDTA with pH 9.0 and EDTA with 
pH 8.0. 
 
MICROWAVE ANTIGEN RETRIEVAL: 
 This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections in 
various buffers for rapid and uniform heating. Antibodies against Ki67 and 
MIB-1 work well after heat pretreatment in this method. 
 
PRESSURE COOKER ANTIGEN RETRIVEL:                            
 Miller et al. in 1995 compared and proved that pressure cooking method 
has fewer inconsistencies, less time consuming and can be used to retrieve 
large number of slides than in microwave method.[70] 
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PITFALLS OF HEAT PRETREATMENT: 
i. Drying of sections at any stage after heat pretreatment destroys 
antigenicity.  
ii. Nuclear details are damaged in poorly fixed tissues.  
iii. Fibers and fatty tissues tend to detach from slides while heating. 
iv.  Not all antigens are retrieved by heat pretreatment and also some 
antigens like PGP 9.5 show altered staining pattern. 
 
ANTIGEN DETECTION SYSTEMS: 
 After retrieval specific antibodies are added to the tissue section which 
binds to the antigens forming antigen antibody complex. The methods 
employed are the direct and indirect methods.  
 
 Direct method is a one step method in which primary antibody 
conjugated with the label directly react with antigen. Most commonly used 
labels are flouro-chrome, horse radish peroxidase and alkaline phosphatase.  
 
 Indirect method is a two-step method in which labelled secondary 
antibody reacts with primary antibody bound to specific antigen. This method 
is more sensitive than direct method as it has better signal amplification.[65] 
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USES OF IMMUNOHISTOCHEMISTRY IN BREAST 
PATHOLOGY [71] 
 High molecular weight cytokeratins - Distinguish usual 
ductal hyperplasia from ductal carcinoma in situ. 
 Myoepithelial markers to assess stromal invasion. 
 E Cadherin   - differentiate ductal from lobular carcinoma. 
 To differentiate primary from secondary metastatic tumors 
 To establish site of origin in metastatic tumors 
 Cytokeratin stains to detect sentinel lymph nodes metastasis. 
 Assessment of Estrogen, Progesterone receptor  & HER2neu for 
prognostic    significance  
 For  molecular classification of breast carcinoma 
 To distinguish metaplastic carcinoma from mesenchymal lesion.   
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CD10 –common acute lymphoblastic leukemia antigen (CALLA) 
 It is a cell surface neutral endopeptidase expressed both in 
haematopoeitic and non haematopoeitic cells. 
 
 Haematopoeitic cells - it is taken up by precursor cell especially 
precursor B cell and in germinal centre. One of the first marker to identify 
ALL - hence its name. 
 
 Also expressed in other lymphomas like - angioimmunoblastic 
lymphoma, follicular lymphoma, Burkitt lymphoma, diffuse large B cell 
lymphoma, mantle and marginal zone lymphoma 
 
 Non haematopoeitic cells - It is expressed in variety  of normal tissue 
including brush border of epithelial cells of small intestine and proximal tubule 
of kidney, myoepithelial cells of breast, endometrial stromal cells, liver..etc. 
 
 It is the specific marker for renal cell carcinoma especially of clear cell 
type and is the commonly used marker in metastatic tumor of renal origin.     
 
 Other neoplasm where it has been extensively studied is endometrial 
stromal tumor and its role in differentiating it from smooth musle tumor of the 
uterus. 
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 Other lesion where CD10 used are transitional cell carcinoma, prostatic 
carcinoma, hepatocellular carcinoma, colonic carcinoma, mesonephric 
remanant, solid and pseudopapillary tumor of pancreas, leiomyosarcoma, and 
hemangiopericytoma.  
 
 CD10 is a metalloproteinase which degrades many bioactive peptides. 
Thus its expression   may provide tumors the capacity to infiltrate adjacent 
tissue and invade blood vessels thereby increasing the metastatic potential of 
the tumor. 
 
 This hypothesis was supported by study conducted by Iwaya et al.[72] 
Where increased stromal expression of CD10 in invasive ductal carcinoma is 
associated with increased lymph node metastasis. 
 
 Similar observation was made by ogawa et al.[73] in colorectal carcinoma 
where its expression in severe dysplasia, intramucosal and invasive 
adenocarcinoma is significantly higher compared to adenoma with mild to 
moderate dysplasia. Furthermore invasive growth front shows the higher 
expression of CD10. 
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Role of CD10 in breast lesions 
 CD10 is expressed in myoepithelial cells of human breast and is 
considered specific as luminal epithelial cells and surrounding stromal cells are 
negative for CD10. 
 
 CD10 is found to be expressed in proliferating stromal cells of 
fibroadenoma, phyllodes tumor and epithelial cells exhibiting apocrine 
metaplasia. 
 
 In invasive breast carcinoma, study conducted by Iwaya et al. showed 
that  stromal CD10 expression is significantly associated  with lymph node 
metastasis rather than with histological grade or clinical staging.[72] 
 
 Only few studies are available regarding expression of CD10 in 
phyllodes tumors. Expression tends to occur in subepithelial location where 
stromal condensation occurs. CD10 expression was found to be varying, with 
low expression ranging 0 to 6% in benign PTs to 32 to 50% in borderline to 
malignant PTs [74,75] thus help in grading PTs.        
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 Another study conducted by Ibrahim also shows the correlation between 
CD10 expression and tumor grade   with CD10 positvity in 17% of benign, 
60% of borderline and 80% of malignant PTs.[76]              
     
 Masri et al. found a significant association existing between CD10 
expression and metastasis in phyllodes tumor. Metastasis is unlikely to occur 
in CD10 negative tumor indicating its prognostic significance.[77]   
 
 CD10 is a cytoplasmic stain. In phyllodes tumor CD10 expression is 
assessed by the percentage of stromal cells which takes the stain and how 
intensely it is stained (compared to myoepithelial cells). CD10 is considered 
positive if stromal cells show moderate to strong intensity of CD10 stain in 
greater than 20% of stromal cells.[74] 
  
 
 
 
 
Materials and Methods 
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MATERIALS AND METHODS 
 
 This study is both prospective and retrospective study of Phyllodes 
tumors of breast in the Institute of Pathology, Madras Medical College and 
Rajiv Gandhi Government General Hospital, Chennai during the period 
between January 2012 and June 2014. 
 
 A total of 28,178 specimens were received in the Institute of Pathology, 
Madras Medical College during the period of January 2012 – June 2014 for 
histopathological examination. Out of that, 1931 specimens were breast 
specimens. 
 
 Of these 1931 breast specimens 83 were phyllodes tumor. Among these 
83 specimens, benign, borderline and malignant phyllodes tumors were 70, 6 
and 7 respectively. Of these 83 phyllodes tumor specimens, 31 were simple 
mastectomy, 26 were wide local excision, 2 were lumpectomy, 15 were trucut 
biopsies and 9 were incisional biopsies. 
 
SOURCE OF DATA: 
 The patients attending the surgical outpatient department with the 
complaint of lump or pain were subjected to incision/ trucut/wide local 
excision biopsies or simple mastectomy based on clinical presentation, 
radioimaging and FNAC report. Cases reported as benign, borderline and 
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malignant phyllodes tumor in the Institute of pathology, Madras medical 
college from January 2012 to june 2014 were taken. 
 
INCLUSION CRITERIA: 
 Phyllodes tumor reported in breast specimens irrespective of the 
age. 
 Both small and large biopsy of phyllodes tumor irrespective of 
procedure done. 
 
EXCLUSION CRITERIA: 
 Fibroadenoma and other benign lesions. 
 Other malignant tumors. 
 
METHOD OF DATA COLLECTION: 
 Detailed history of the cases regarding age, clinical findings, site, 
radioimaging finding, FNAC and type of procedure done were obtained for all 
the phyllodes tumor reported during the period of study from surgical 
pathology records. 
 
 Hematoxylin and Eosin stained 4 µ thick sections of the paraffin tissue 
blocks of specimens were reviewed. The following clinical and pathological 
parameters were evaluated: Age, clinical findings, tumor size, tumour site, 
BIRADS score , FNAC, tumor grade and infiltration. 
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 Phyllodes tumor cases were graded into benign, borderline and 
malignant based on cellular atypia, stromal cellularity, stromal overgrowth, 
mitosis and marginal status.  
 
 Out of 83 cases, 50 cases comprising 38 benign tumors, 6 borderline 
tumors and 6 malignant phyllodes tumor were randomly selected  and their 
representative formalin fixed paraffin embedded tissue samples were subjected 
to immunohistochemistry for CD10. 
 
IMMUNOHISTOCHEMICAL EVALUATION: 
 Immuohistochemical analysis of markers CD10 were done in paraffin 
embedded tissue samples using Super-sensitive polymer HRP system based on 
non-biotin polymeric technology. Four micron thick sections from formalin 
fixed paraffin embedded tissue samples were transferred onto gelatin coated 
slides. Heat induced antigen retrieval was done. The antigen was bound with 
mouse monoclonal antibody (Pathnsitu) against CD10 antigen and then 
detected by the addition of secondary antibody conjugated with horse radish 
peroxidase-polymer and diaminobenzidine substrate. The step by step 
procedure of Immunohistochemistry is given below. 
  
47 
 
 
Antigen Vendor Species(clone) Dilution Positive control 
CD10 Pathnsitu Mouse Ready to use 
Internal control 
(Myoepithelial 
cells of breast) 
 
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 μ were cut from formalin fixed 
paraffin embedded tissue samples and transferred to gelatin-chrome 
alum coated slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections were deparaffinised in xylene for 15 minutes x 2 
changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes for 
2 changes. 
5. The sections were then washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
 
Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. This 
step unmasks the antigenic determinants of fixed tissue sections. 
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2. The slides were then cooled to room temperature for 20 minutes and 
washed in running tap water for 5 minutes. 
3. The slides were then rinsed in distilled water for 5 minutes. 
4. They were washed with appropriate wash buffer (phosphate buffer) 
for 5 minutes x 2 changes. 
5. Peroxide block was applied over the sections for 5 minutes with 
polyexcel H2O2. 
6. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
 
Antibody application: 
1. The sections were drained (without washing) and appropriate 
primary antibody was applied over the sections and incubated for 30 
minutes. 
2. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
3. The slides were covered with target binder and incubated for 10 
minutes at room temperature. 
4. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
5. The slides were covered with Polyexcel polyHRP for 10 minutes. 
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6. The slides were washed in phosphate buffer for 5 minutes x 2 
changes. 
 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of polyexcel 
stunnDAB chromogen to 1 ml of StunnDAB buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
3. The slides were washed in distilled water for 2 minutes. 
4. The sections were counterstained with Hematoxylin  for 2 seconds. 
5. The slides were washed in running tap water for 5 minutes. 
6. The slides were air dried, cleared with xylene and mounted with 
DPX. 
 
Alternate methods of antigen retrieval 
 Pressure cooker antigen retrieval 
 Microwave and trypsin antigen retrieval 
 
INTERPRETATION AND SCORING SYSTEM: 
 The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization, percentage of cells stained  
and intensity of staining. 
 
Evaluation of staining:[74] 
Percentage of stomal  cells stained was assessed- 0 to 100%  
50 
 
Intensity was graded ( compared to myoepithelial staining intensity) 
0 - no staining 
1 - weak  
2  - moderate 
3  - strong 
 
Interpretation 
Positive- intensity 2 or 3 in >20% cells 
Negative- intensity 0 or 1 even in >20 cells 
- Intensity 2 or 3 in <20% cells. 
 
Data entry: 
 All the data collected and the results obtained were entered into Excel 
2007. 
 
STATISTICAL ANALYSIS: 
 The statistical analysis was performed using statistical package for 
social science software version SPSS 17.0. The p value was considered 
significant if below 0.05. 
  
 
 
 
 
Observation and Results 
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OBSERVATION AND RESULTS 
 
 In a study period of 30 months cases were taken both retrospectively 
and prospectively from January 2012 to june 2014. During this period, a total 
of 28,178 specimens were received in the Institute of pathology, Madras 
Medical College for histopathological examination. Of these 1931 were breast 
specimens constituting 6.9%. 
 
 Out of 1931 breast specimen received 83 were reported as phyllodes 
tumor accounting for 4.2%.  
 
Table 1: Distribution of cases based on histological subtype 
 
S.No Type of tumor Total no of cases Percentage 
1 Benign 70 84.3% 
2 Borderline 6 7.2% 
3 Malignant 7 8.4% 
 
 The most common histological subtype of phyllodes tumor is benign 
constituting 84.3% whereas borderline and malignant constitute only 7.2% and 
8.4% respectively (Table 1 & chart 1). 
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Chart 1: Distribution of cases based on histological subtypes 
 
 
 Out of the total 83 cases, 50 were taken randomly (38 benign, 6 
borderline and 6 malignant tumor). 
 
Table 2:  Distribution of phyllodes tumor according to age 
Age No of cases Percentage 
≤30 8 16% 
31-40 12 24% 
41-50 18 36% 
51-60 12 24% 
Total no of cases 50 100% 
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Chart 2: Distribution of tumor according to age 
 
 
 In this study most of the phyllodes tumors occur in the age group of 41-
50 comprising 36% followed by age group of 31-40 and 51-60 comprising 
24% each age respectively. Only 16% occur in the age group less than 30 
years (Table 2 and chart 2). 
 
 Benign tumor had a peak incidence in the age group of 41-50 years. The 
youngest and oldest age of presentation observed was 17 years and 57 years 
respectively with mean of 39.7.  
 
 In case of borderline peak incidence occur in the age group betwen 
51and 60 years with youngest and oldest age of presentation of 35 and 60 
years respectively with mean of 47.8 years. 
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 Of malignant lesions peak incidence was seen at 51- 60 years with 
youngest and oldest age of presentation observed was 51years and 60 years 
respectively with mean of 54 years. (Table 3 & 4 and chart 3 & 4)  
 
Table 3: Age distribution in different subtypes 
Age Benign(%) Borderline(%) Malignant(%)  
≤30 8 (21.05%) -- -- 
31-40 11 (28.94%) 1 (16.67) -- 
41-50 16 (42.11%) 2 (33.33) -- 
51-60 3 (7.89%) 3 (50%) 6 (100%) 
Total no of cases 38(100%) 6(100%) 6(100%) 
 Pearson chi square test :   Test value - 27.290  
                                          P value - 0.001 
 
Chart  3: Age distribution in different subtypes 
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Table 4: Relationship between patients age and tumor grade 
Tumor grade Youngest age Oldest age Mean 
Benign 17 57 39.7 
Borderline 35 60 47.8 
Malignant 51 60 54 
  
Chart 4: Mean age distribution in different grade 
 
 
 Depending on the size, distribution of cases were as shown in table 5 
and chart 5. Most of the lesions (46%) had the size range of  6-10cm,44% had 
1-5 cm size and only 10% of  the cases were more than 10cm.     
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Table 5: Distribution of cases according to size 
Size No of cases Percentage 
1-5 22 44% 
6-10 23 46% 
>10 5 10% 
Total no of cases 50 100% 
 
Chart 5: Distribution of cases according to size 
 
 
 Most of the benign tumors were of the size 1-5cm (55.26%) followed by 
39.47% were of size 6-10cm with only 5.265 had size greater than 10cm. 
 
 Of borderline tumors most (66.67%) were of size 6-10cm, with 16.67% 
is of size 1-5cm and greater than 10cm  each respectively. 
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 Among malignant tumors 66.67% of cases were of size 6-10cm, 33.33% 
were of size greater than 10cm and none of the cases were less than 5cm 
(Table 6 & Chart 6). 
 
Table 6: Distribution of size in different subtypes 
Size Benign (%) Borderline (%) Malignant (%) 
1-5 21 (55.3%) 1 (16.7%) -- 
6-10 15 (39.5) 4 (66.7%) 4 (66.7%) 
>10 2 (5.3%) 1 (16.7%) 2 (33.3%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
Pearson chi square test:  Test value - 10.606 
                                  P value      -  0.031 
 
Chart 6: Distribution of size in different subtypes 
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Table 7: Relationship between tumor size and tumor grade 
Size Smallest size (cm) 
Largest size 
(cm) 
Mean 
(cm) 
Benign 3 15 5.6 
Borderline 5 14 8.5 
Malignant 7 19 10.8 
 
 In this study , benign tumor size ranges from 3cm to 15 cm in maximum 
diameter with mean size of 5.6cm. Size of borderline tumor ranges from 5cm 
to 14cm with mean of 8.5cm. 
 
 In 6 cases of malignant tumor the size ranged from 7cm upto 19cm with 
mean of 10.8cm (Table 7 and Chart 7). 
 
Chart 7: Relation between tumor size and tumor grade 
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Table 8: Distribution of cases according to laterality 
Side No of cases Percentage 
Right 32 64% 
Left 17 34% 
Bilateral 1 2% 
Total 50 100% 
 
Chart 8: Distribution of cases according to laterality 
 
 
  One case of benign tumor was bilateral remaining cases most often 
occur in right side which accounts for 64% (32 cases) and left side with 
17cases accounting for 34% ( Table 8 & 9,chart 8 &9). 
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Table 9: Distribution of laterality in different grade 
Side Benign (%) Borderline(%) Malignant(%) 
Right 26 (68.42%) 1(16.67%) 5(83.33%) 
Left 11(28.94%) 5(83.33%) 1(16.67%) 
Bilateral 1(2.63%) -- -- 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 7.993 
                                 P value        - 0.092 
 
Chart 9: Distribution of laterality in different grade 
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Table 10: Distribution of cases according to tumor location 
Tumor location No of cases Percentage 
Upper outer 
quadrant(UOQ) 19 38% 
Upper inner 
quadrant(UIQ) 5 10% 
Lower outer 
quadrant(LOQ) 7 14% 
Central quadrant(CQ) 11 22% 
All quadrant(AQ) 8 16% 
Total  50 100% 
 
  
Chart 10: Distribution of cases according to tumor location  
 
 
In this study the most common site of tumor location was found to be the 
upper outer quadrant corresponding to 38%, followed by central quadrant with 
0
2
4
6
8
10
12
14
16
18
20
UOQ UIQ LOQ CQ AQ
19
5
7
11
8
N
O
 O
F 
CA
SE
S
QUADRANT
NO OF CASES
62 
 
22%,all quadrant with 16.0% , lower outer quadrant with 14.0%and the least 
common site was the upper inner quadrant with 10.0%. No cases were found 
in lower inner quadrant as shown in the Table 10 and Chart 10. 
                   
 Among the subtypes , benign occur more commonly in upper outer 
quadrant (44.7%) whereas most  (50%) of borderline and malignant involves 
any of the quadrants of breast (Table 11). 
 
Table 11 :Association of tumor location with different subtypes 
Tumor location Benign (%) Borderline(%) Malignant (%) 
UOQ 17(44.7%) 1(16.7%) 1(16.7%) 
UIQ 4(10.5%) 1(16.7%) -- 
LOQ 6(15.8%) -- 1(16.7%) 
CQ 9(23.7%) 1(16.7%) 1(16.7%) 
AQ 2(5.3%) 3(50.0%) 3(50.0%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 15.338 
                                 P value        -  0.053 
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 Out of 50 cases, most of the cases belonged to BIRADS IV comprising 
46%,followed by BIRADS III 38% and BIRADS II & IV each constituting 8% 
respectively (table 12 and chart 11). 
 
 Most of the benign tumors belong to BIRADS IV and III (44.7% and 
42.1%) with only few cases have BIRADS II and V. 
 
 Borderline also shows similar findings with most of the cases belonging 
to BIRADS IV and III with 66.7% and 33.3% respectively whereas most of 
malignant tumors belong to BIRADS V with 50.0% followed by BIRADS IV 
and III, found to be 33.3% and 16.7% each (Table13 and chart 12). 
 
Table 12: Distribution of cases according to BIRADS 
BIRADS No of cases Percentage 
1 -- -- 
2 4 8% 
3 19 38% 
4 23 46% 
5 4 8% 
Total 50 100% 
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Chart 11:Distribution of cases according to  BIRADS 
 
 
Table 13: BIRADS findings in individual subtypes 
BIRADS Benign(%) Borderline (%) Malignant (%) 
1 -- -- -- 
2 4(10.5%) -- -- 
3 16(42.1%) 2(33.3%) 1(16.7%) 
4 17(44.7%) 4(66.7%) 2(33.3%) 
5 1(2.6%) -- 3(50.0%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test:  Test value    - 18.043 
    P value        -  0.006 
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Chart 12: BIRADS finding in individual cases 
 
 
Chart 13: Distribution of cases based on clinical features 
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Table 14: Distribution of cases based on clinical features 
Clinical features No of cases Percentage 
Lump 41 82% 
Lump & pain 8 16% 
Lump, pain & nipple 
discharge 1 2% 
Total 50 100% 
 
 On analysing 50 cases, 41 cases (82%) presented only with lump and 
8cases (16%) presented with both lump and pain. Only one case (2%) 
presented with nipple discharge (ND) along with lump and pain and was found 
to belong to malignant category( Table 14 &15 and chart 13). 
 
Table 15: Distribution of clinical presentation in different subtypes 
Clinical features Benign (%) Borderline (%) Malignant (%) 
Lump 34(89.5%) 4(66.7%) 3(50.0%)) 
Lump & pain 4(10.5%) 2(33.3%) 2(33.3%) 
Lump, pain & 
nipple discharge -- -- 1(16.7%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test : Test value  - 11.478 
                                 P value      -  0.022 
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Table 16: Distribution of cases in relation to surgical biopsy specimens 
 
Procedure done No of cases Percentage 
Incision biopsy 3 6% 
Trucut biobsy 9 18% 
Lumpectomy 1 2% 
Wide local excision 19 38% 
Simple mastectomy 18 36% 
Total 50 100% 
 
 Of the 50 cases, resected specimens include 38 cases whereas small 
biopsy were 12 case. Of the resected specimens commonest type of surgical 
biopsy was wide local excision constituting 38% followed by simple 
mastectomy which constitutes 36%(Table 16 and chart 14). 
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Chart 14: Distribution of cases in relation to surgical biopsy specimens 
 
  
 Gross involvement of margins are assessed only in resected specimens 
and small biopsies are not included. Out of 50 cases, 38 were resected 
specimen and 1 was lumpectomy for which marginal status could not be 
assessed.  
 
 Out of 37 cases 9 cases show infiltration into adjacent breast tissue 
whereas 28 cases shows pushing margin (Table 17 And chart 15). 
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Table 17: Gross margin in different subtypes 
Gross margin Benign (%) Borderline (%) Malignant (%) 
Infiltrative -- 4(66.7%) 5(83.3%) 
Pushing 28 (73.7%) -- -- 
Margin not 
known 10(26.3%) 2 (33.3%) 1(16.7%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
 Pearson chi square test: Test value  - 38.132 
                                   P value       -  0.001 
 
Chart 15: Gross margin in different subtypes 
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Table 18: Association of atypia in different subtypes 
Atypia Benign (%) Borderline (%) Malignant(%) 
No atypia 26(68.4%) -- -- 
Minimal 12(31.6%) -- -- 
Moderate -- 6(100%) -- 
Marked -- -- 6(100%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 100 
                                 P value        -  0.001 
 
Chart 16: Association of atypia in different subtypes 
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            Among different subtypes  atypia is more maked in all cases (100%) of 
malignant phyllodes tumor , with moderate atypia in all cases of borderline 
tumor. In benign tumors 68.4% shows no atypia of stromal cells but 31.6% 
shows minimal atypia(Table 18 and chart 16). 
 
Table 19: Association of stromal cellularity in different subtypes 
Stromal 
cellularity Benign (%) Borderline(%) Malignant(%) 
Minimal 33(86.8%) 1(16.7%) -- 
Moderate 5(13.2%) 4(66.7%) 1(16.7%) 
Marked -- 1(16.7%) 5(83.3%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 100 
                                 P value        -  0.001 
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Chart 17: Association of stromal cellularity in different subtypes 
 
 
 
 Regarding stromal cellularity, benign tumors shows minimal cellularity 
in 86.8% and moderate cellularity in 13.2%. Nine of benign show marked 
cellularity. Most of borderline tumors have moderate cellularity in 66.7%, with 
mild and marked cellularity seen in 16.7% of cases each. Most of malignant 
tumors have marked cellularity accounting for 83.3% followed by 16.7% 
showing moderate cellularity(Table 19 and chart 17). 
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Table 20: Association of stromal overgrowth in different subtypes 
Stromal 
overgrowth Benign (%) Borderline (%) Malignant (%) 
Minimal 36(94.7%) 1(16.7%) -- 
Moderate 2(5.3%) 5(83.3%) 1(16.7%) 
Marked -- -- 5(83.3%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 65.721 
                                 P value        -  0.001 
 
Chart 18: Association of stromal overgrowth in different subtypes 
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 Stromal overgrowth is marked in most (83.3%) of the malignant tumors 
with only 16.7% showing moderate overgrowth. Whereas most of benign 
tumors show minimal cellularity (94.7% of cases), with only 5.3% have 
moderate cellularity. Among borderline 83.3% show moderate cellularity and 
16.7% show minimal cellularity (Table 20 and chart 18). 
 
 As that of gross margin, microscopic involvement of tumor margin are 
assessed only in 37 cases of resected margin. Out of 5 cases of malignant 
tumor four showed margin involvemen . Out of 4 cases of borderline two 
showed margin involvement whereas in 28 cases of benign only three showed 
margin involvement (Table 21 and chart 19). 
 
Table 21: Association of microscopic margins in different subtypes 
Microscopic 
margin Benign(%) Borderline(%) Malignant(%) 
Uninvolved 25(65.8%) 2(33.3%) 1(16.7%) 
Involved 3(7.9%) 2(33.3%) 4(66.7%) 
Margin not 
known 10(26.3%) 2(33.3%) 1(16.7%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
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Chart 19: Association of microscopic margins in different subtypes 
 
 
Table 22: Association of mitosis in different subtypes 
 Benign(%) Borderline (%) Malignant(%) 
0-4/10Hpf 38(100.0%) -- -- 
5-9/10Hpf -- 6(100.0%) -- 
>10/10Hpf -- -- 6(100.0%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 100 
                                 P value        -  0.000 
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IHC interpretation 
Table 23: CD10 Intensity of stain in different subtypes 
 Benign (%) Borderline (%) Malignant(%) 
No staining 18(47.4%) 1(16.7%) -- 
Weak 14(36.8%) 1(16.7%) -- 
Moderate 5(13.2%) 1(16.7%) 2(33.3%) 
Strong 1(2.6%) 3(50.0%) 4(66.7%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 26.151 
                                P value        -  0.000 
 
 CD10 stain intensity was compared with myoepithelial cells and 
intensity grade was given as weak, moderate and severe. 
 
 Among benign tumor most cases(47.4%) show no staining in stromal 
cells whereas 36.8%,13.2% and 2.6% of cases show weak, moderate and 
intense staining . 
 
 In borderline tumor 50.0% cases show strong intensity of stain in 
stromal cells. 
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 Of malignant tumors most cases (83.3%) show strong intensity and only 
33.3% shows moderate intensity (Table 23 and chart 20). 
 
Chart 20: CD10 Intensity of stain in different subtypes 
 
 
Table 24: percentage of cells stained in different subtypes 
 Benign(%) Borderline(%) Malignant(%) 
Nil 18(47.4%) 1(16.7%) -- 
<20% cells 13(34.2%) 1(16.7%) 1(16.7%) 
>20% cells 7(18.4%) 4(66.7%) 5(83.3%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 14.083 
                                 P value     -  0.007 
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 Out of 6 cases of malignant tumor, in five cases greater than 20% of 
cells have taken stain and only one case show staining in less than 20% of 
cells. In borderline tumor also 50% (3 out of 6 cases) cases shows staining in 
greater than 20% of cells. 
 
 Among benign out of 38 cases only 7 cases(13.4%) show staining in 
greater than 20% of stromal cells (table 24 and chart 21). 
 
Chart 21: percentage of cells stained in different subtypes 
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Table 25:  CD10 interpretation 
 No of cases Percentage 
CD10 positive 11 22% 
CD10 negative 39 78% 
Total 50 100% 
 
 Out of 50 cases of phyllodes tumor 11 cases show CD10 positive 
accounting for 22% and 39 cases are CD10 negative accounting for 78% 
(Table 25 and Chart 22) 
 
 
Chart 22:  CD10 interpretation 
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Table 26: CD10 positivity/negativity in different subtypes 
 Benign (%) Borderline (%) Malignant (%) 
CD10 positive 3(7.9%) 3(50.0%) 5(83.3%) 
CD10 negative 35(92.1%) 3(50.0%) 1(16.7%) 
Total no of cases 38 (100%) 6 (100%) 6 (100%) 
 
Pearson chi square test: Test value    - 20.300 
                                 P value        - 0.000 
 
 
Chart 23: CD10 positivity/negativity in different subtypes 
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        Out of 50 cases of phyllodes tumor, CD10 positivity was more in case of 
malignant tumor (6 out of 5) accounting for 83.3% with only one case (16.7%) 
being CD10 negative. 
 
 Among borderline 50% show CD10 positive while remaining 50% were 
negative. 
 
 Of benign tumors, out of 38 cases 35 (92.1%) were CD10 negative with 
only 3 cases accounting for 7.9% were CD10 positive (Table 26 and chart 23). 
  
 
 
 
 
Colour Plates 
  
  
Fig.2: 3728/14- Benign phyllodes tumor- solid homogenous circumscribed 
mass with with pushing margin 
 
 
 
Fig 3:5695/12- Borderline phyllodes tumor- solid growth with 
pushing margin 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: 6119/14- Malignant phyllodes tumor-solid growth with  
focal cystic spaces with infiltrative margin. 
 
  
  
BENIGN PHYLLODES TUMOR 
 
  
Fig 5: Benign tumor-Increased tromal 
cellularity with monotonous spindle cell. 
100x, HPE- 7917/13 
Fig 6: spindle cell with bland nuclei. 
No atypia and mitosis seen.   
400x, HPE- 7917/13 
 
 
  
Fig 7: IHC –CD10 positive only in 
myoepithelial cells. 100x, HPE- 7917/13 
Fig 8: IHC- Stromal  cells negative for 
CD10 . 400x, HPE- 7917 
 
  
  
BENIGN PHYLLODES TUMOR 
 
  
Fig 9: Benign tumor –Increased stromal 
cellularity . 100x, HPE- 2914/14 
Fig 10: Benign spindle cells, no atypia . 
400x, HPE- 2914/14 
 
 
  
Fig 11: IHC:CD10 positive in 
Myoepithelial cells and  >20% stromal 
cell taken stain . 100x, HPE- 2914/14 
Fig 12: IHC CD10 - 2+ staining in >20% 
stromal cells. 400x, HPE- 2914/14 
 
 
  
BORDERLINE PHYLLODES TUMOR 
 
  
Fig 13: Borderline  tumor –Increased 
stromal cellularitywith atypia . 100x, 
HPE- 8626/13 
Fig 14: spindle cell with mild to moderate 
atypia with occasional mitosis . 400x, 
HPE- 8626/13 
 
 
  
Fig 15: IHC->20% stromal cells positive 
for CD10. 100x, HPE- 8626/13 
Fig 16: CD10 – 3+ staining in >20% 
stromal cells. 400x, HPE- 8626/13 
 
 
 
  
BORDERLINE PHYLLODES TUMOR 
 
  
Fig 17: Borderline  tumor –Increased 
stromal cellularity and  stromal 
overgrowth. 100x, HPE- 9524/12 
Fig 18: spindle cell with mild atypia with 
occasional mitosis . 400x, HPE- 9524/12 
 
 
 
                
Fig 19:IHC- Stromal cells negative for 
CD10 . 100x, HPE- 9524/12 
 
Fig 20:IHC-Stromal  cells negative for 
CD10 . 400x, HPE- 9524/12 
 
 
 
  
MALIGNANT PHYLLODES TUMOR 
 
  
Fig 21: Malignant  tumor –Marked 
stromal overgrowth with increased 
mitosis . 100x, HPE- 5025/14 
Fig 22: Marked atypia of cells  with  
prominent nucleoli and tumor giant cells 
seen. 400x, HPE- 5025/14 
 
 
  
Fig 23: IHC – >20% stromal cells positive 
fot CD10. 100x, HPE- 5025/14 
 
Fig 24: IHC CD10– 3+ staining in >20% 
stromal cells . 400x, HPE- 5025/14 
   
 
 
 
 
Discussion 
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DISCUSSION 
 
 Phyllodes tumor is a rare fibroepithelial tumor accounting for  <1% of 
all primary breast tumors and constitute 2.5% of fibroepithelial tumors. Annual 
incidence is estimated to be 2.1 per million women in a population based study 
conducted in USA. 
 
 Age group most commonly affected are between 35 and 55 years with 
peak incidence of 45 years. 
 
 Behaviour of Phyllodes tumor varies from completely benign to highly 
malignant tumor. Thus phyllodes tumor has been subclassified into benign and 
malignant with some category not fitting into both will come under borderline 
category. 
 
 This classification is mainly based on histological features including 
cellularity, cellular and nuclear atypia, overgrowth of stroma, marginal status 
whether infiltrative or pushing margin and number of mitosis per 10 high 
power field. 
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 Though benign tumors are indolent, it sometimes has aggressive growth 
with local recurrence but do not metastasize whereas it is common in 
malignant phylodes tumor. Thus grading of tumor has important prognostic 
significance. 
 
 In the current study an attempt has been made to study the clinical, 
radiological and histomorphological features of 50 cases of Phyllodes tumors 
and to determine the role of immunohistochemical markers in determining the 
grading of these tumors. 
 
 Madras medical college being a tertiary referral care centre, the relative 
proportion of breast specimens received for histopathological examination was 
6.9% (1931 out of 28,178) over a period of 30 months. 
 
 Of these 1931 bresat specimens, 83 were reported as phyllodes tumor 
accounting for 4.2% of breast lesions. 
 
 In the current study out of 83 cases, 50 cases were selected in which 38 
were benign, 6 were bordrerline and 6 were malignant. Clinical, 
histomorphological features of these were evaluated and immunohistochemical 
analysis were done using CD10 marker. 
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 Most of the phyllodes tumors are benign and its proportion varies from 
study to study accounting for 35% -65% and the remainder being borderline 
and malignant. Variation in proportion is mainly due to the subjective variation 
in interpretation criteria. 
 
 In current study out of 83 cases reported 70 (84.3%) were benign, 
6(7.2%) were borderline and 7(8.4%) were malignant and all were female 
patients.  
 
COMPARISON OF AGE WITH SUBTYPES OF PHYLLODES 
TUMORS: 
Table 27: Relation between Mean age of patients in different subtypes 
 Benign(yrs) Borderline(yrs) Malignant(yrs) 
Ibrahim WS et 
al76 32.5 49.2 50.2 
Tse GMK et al74 40 45 46 
Kucuk et al78 31.88 -- 48 
Current study 39.7 47.8 54 
  
            According to Ibrahim et al76, the mean age of benign, borderline and 
malignant tumors were 32.5, 49.2 and 50.2 years respectively (Table 27). 
 
85 
 
 According to Tse GMK et al74 the mean age of  benign tumors was 40 
years, whereas mean age of borderline and malignant phyllodes tumors were 
45 and 46 years respectively (Table 27). Overall mean age is 42 years. 
 
 In the study by Kucuk et al78, only benign and malignant tumors were 
compared mean age was found to be 31.88 and 48years respectively (Table 
27). 
 
 In the current study the age range of benign tumor was 17 to 57years  
with mean age of 39.7years. In case of borderline tumors, age ranges from 35 
to 60 years with mean of 47.8 years whereas in malignant phyllodes tumor age 
ranges from 51 to 60years with mean of 54 years. 
 
 In the current study most of benign and borderline tumors occur in the 
age group of 41 to 50 years whereas most malignant tumors occur in age group 
0f 51 to 60 years. Overall, phyllodes tumor is common in age group of 41 to 
50 years with mean of 42.4 years according to our study. 
 
 When we compare age with subtypes we have significant P value of 
0.001 which is less than 0.05. Thus in the current study, age increases with 
increasing grade of tumor which is similar to other studies conducted. 
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COMPARISON OF SIZE WITH SUBTYPES: 
      
Table 28: comparison of mean size with subtypes 
 Benign (cm) Borderline(cm) Malignant(cm) 
Ibrahim WS et 
al76 2.8 8.1 16 
Tse GMK et al74 4 5.4 6.5 
Current study 5.6 8.5 10.8 
  
         According to Ibrahim WS et al76, the mean size was 2.8cm in case of 
benign tumors. In borderline tumors mean size is about 8.1 cm and malignant 
tumors shows a mean size of 16 cm (Table 28). 
 
 According to Tse GMK et al74, the mean size of benign, borderline and 
malignant tumors were 4cm, 5.4cm and 6.5cm respectively. Overall mean size 
of phyllodes tumor in this study is 4.8cm (Table 28). 
 
 According to Masri et al77, mean size of phyllodes tumor was 7.1 cm 
whereas according to Onkendi EO et al79 mean size is about 8.3cm. 
  
 In the current study the minimum and maximum size of benign, 
borderline and malignant tumor were 3-15cm, 5-14cm and 7-19cm 
87 
 
respectively. Mean size of benign tumors was 5.6 cm, borderline was 8.5 cm 
and malignant tumor were 10.8cm with overall mean of 6.6cm. 
 
 In the current study most of benign tumors were of size 1-5cm, with 
most of borderline and malignant tumors were of size 6-10cm. 
 
 Most of the studies show no correlation between size and subtypes of 
phyllodes tumor.  
 
 When we compare size of tumor with subtypes in present study we have 
a P value of 0.031, thus showing association between tumor size and tumor 
grade. 
 
COMPARISON OF SIDE OF PHYLLODES TUMOR: 
 
Table 29: comparison of side of phyllodes tumor 
 Right(%) Left(%) Bilateral(%) Total  
Chao TC et al30 
(%) 22(61.1%) 14(38.9%) -- 
 
36(100%) 
Onkendi EO79 
(%) 37(55.2%) 30(44.7%) -- 
 
67(100%) 
Current study 
(%) 32(64%) 17(34%) 1(2%) 
 
50(100%) 
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 According to Chao et al30, out of 36 cases twenty two tumors occur in 
right side accounting for 61.1% whereas 14 cases accounting for 38.9% occur 
in the left side (Table 29). 
 
 According to Onkendi et al79, out of 67 cases 37 had tumor in the right 
side accounting for 55.2% whereas thirty had tumor in left side of breast 
accounting for 44.7% (Table 29). 
 
 In a study conducted by Zissis et al80, out of 84 cases 2 had bilateral 
involvement accounting for 2.4%. 
      
 In the current study out of 50 cases  32 cases had occurance in right side  
accounting for 64% and 17 had left side accounting for 34%. 0f 50 cases one 
show bilateral occurence accounting for 2%. 
 One case with bilateral lesion is found to be benign. 
 
 In the current study when side is compared with phyllodes tumor we had 
a P value of 0.092, hence there is no significant association between the two. 
 
COMPARISON OF TUMOR LOCATION WITH SUBTYPES: 
 According to Mishra SP et al5, phyllodes tumor most commonly found 
in upper outer quadrant. 
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 In the current study most common location of phyllodes tumor is upper 
outer quadrant estimated to be 38% followed by central quadrant with 22%, 
involving all quadrant in 16%, lower outer quadrant in 14% and upper inner 
quadrant with 10%. 
 
 In the current study most common location is upper outer quadrant 
which correlated with the above study. 
 
 Most of benign tumor occur in upper outer quadrant whereas borderline 
and malignant involve all quadrants of breast which may be due to larger size 
of the tumor in these lesion. 
 
 P value is not found to be significant when location is compared with 
different subtypes. 
 
COMPARISON OF CLINICAL PRESENTATION WITH SUBTYPES: 
 Lump is the most common clinical presentation accounting for 82% 
with lump and pain being next common presentation of about 16% in the 
current study.      
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 In one case, in addition to pain and lump, it is associated with nipple 
discharge which may be due to some associated lesion. 
 
COMPARISON OF RADIOIMAGING WITH SUBTYPES: 
 In the current study, based on BIRADS score most of the phyllodes 
tumor come under score IV. 
 
 Among benign most belong to BIRADS IV and III accounting for 
44.7% and 42.1% respectively. In borderline most belong to BIRADS IV 
whereas most of malignant tumors belong to BIRADS V. 
 
 P value of 0.006 is obtained when compared with subtypes which is 
significant. 
 
COMPARISON OF TYPE OF SURGERY WITH SUBTYPES: 
           In a study conducted by Onkendi EO et al[79] , out of 67 cases wide local 
excision was done for 32 cases accounting for 47.8% whereas 35 were treated 
by mastectomy amounting 52.2% 
 
 In this study out of 50 cases, 38 were resected specimen and most 
common surgery done in our institution for  phyllodes tumor are  wide local 
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excision and mastectomy which constitute 50% and 47.4% of resected 
specimen  respectively. 
 
 There is no significance in the type of surgery done in both studies, as it 
depend mainly on the size of tumor. 
 
COMPARISON OF MICROSCOPIC APPEARANCE WITH 
SUBTYPES: 
Cellularity: 
 According  to Ho SK et al80 , most of benign tumors show mild 
cellularity with 72.5% and borderline tumor have moderate cellularity with 
68.75% and malignant tumor   have both moderate and marked cellularity with 
52.9% and 47.1%.                  
 
 Similar findings are obtained in the current study in benign and 
borderline, with 86.8% of benign have minimal cellularity and 66.7% show 
moderate cellularity whereas malignant shows marked cellularity in 83.3% 
with only 16.7% have moderate cellularity. 
 
 With P value of 0.001 there is strong association between stromal 
cellularity and tumor grade. 
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 According to Ho SK et al80, increase in stromal cellularity is absent in 
most of benign and borderline tumors and only 17.6% show marked stromal 
overgrowth. 
 
 Whereas in current study stromal overgrowth is minimal or absent in 
most of benign tumors , with minimal to moderate in borderline with marked 
cellularity in malignant with 83.3% with P value of 0.001. 
Atypia: 
 Ho SK et al80 in his study showed most of benign tumors displaying 
mild atypia accounting for 95.8%. In borderline 70.8% have mild atypia and 
29.1% have moderate atypia. In malignant PTs 70.5% show moderate atypia 
with only 17.64%  show severe atypia. 
 
 In the current study, most of benign tumors have no or mild atypia with 
all cases of borderline and malignant have moderate and marked atypia 
respectively.   
         
Mitosis: 
 Mitosis are also more in malignant lesion with almost all cases have 
high mitotic rate of greater than 10 per 10 high power field whereas both 
benign and borderline tumors have less than ten per ten high power field. Both 
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atypia and mitotic figure have significant P value of 0.001 and 0.000 in the 
current study. 
 
Micoscopic margin: 
 In the current study microscopic margin was considered to be positive 
when any one of the resected margin is found to have tumor cells. Here only 
resected specimens (37 cases) were considered excluding one lumpectomy 
specimen.  
 
 Out of 5 malignant lesion 4 (80%) shows positive microscopic margin 
whereas marginal involvement of margins is less in case of benign tumors (3 
out of 28 cases accounting for 10.7%). In borderline 50% (2 out of 4) cases 
show involvement of margin. 
 
 Microscopic margin involvement plays significant role in local 
recurrence. Out of 50 cases, except two cases which were recurrent phyllodes 
all were presenting for the first time. Both recurrent cases were diagnosed to 
be benign phyllodes  with one case having  positive margin in previous biopsy. 
 
 Because of poor compliance, lack of adequate data and shoter duration 
of follow up local recurrence data could not be obtained. 
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IMMUNOHISTOCHEMISTRY: 
CD10 staining intensity: 
 
Table 30: Comparison of intensity of CD10 staining in different subtypes 
 
Masri MA et al[77] Current study 
Benign 
(%) 
Borderline 
(%) 
Malignant 
(%) 
Benign 
(%) 
Borderline 
(%) 
Malignant 
(%) 
No 
staining 0(0%) 4(40%) 1(5.9%) 18(47.4%) 1(16.7%) 0(0%) 
Weak 8(50%) 0(0%) 2(11.8%) 14(36.8%) 1(16.7%) 0(0%) 
Moderate 3(18.8%) 1(10%) 4(23.5%) 5(13.2%) 1(16.7%) 2(33.3%) 
Strong 5(31.3%) 5(50%) 10(58.8%) 1(2.6%) 3(50.0%) 4(66.7%) 
Total 16(100%) 10(100%) 17(100%) 38(100%) 6(100%) 6(100%) 
 
              According to Masri MA et al[77], most of the benign tumor shows 
weak CD10 staining in 50% cases followed by strong (31.3%) and moderate.  
 
 In borderline most cases (50%) show strong CD10 stain and 40% cases 
show no staining. In case of malignant tumors most of the cases (58.8%) show 
strong staining with P value of 0.15% (Table 30). 
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       In the current study CD10 staining intensity was graded by comparing it 
with staining intensity of myoepithelial cells.  Benign tumor shows no staining 
in 18 cases (47.4%) followed by weak, moderate and strong intensity of stain 
in 36.8%, 13.2% and 2.6% respectively.  In borderline tumors 50% of cases 
show strong intensity of stain. Malignant tumor cells show either strong or 
moderate staining intensity  accounting for 66.7% and 33.3%. 
 
 In the current study when we compare intensity of stain with different 
subtypes we get p value of 0.000. So it was found that there is correlation 
between intensity of stain and subtype of tumor. 
 
 For CD10 to be considered positive, greater than 20% of cells should 
have  moderate or strong intensity of stain .  
 
 In the current study out of 6 cases of malignant lesions 5 cases (83.3%) 
show staining in greater than 20% of stromal cells whereas (4 out of 6)66.7% 
of borderline and (7out of 28)18.4% of benign tumors also shows staining in 
greater than 20% of cells. Out of these 16 cases those tumors with cells 
showing moderate to strong intensitry of stain are considered positive. 
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CD10 EXPRESSION IN SUBTYPES OF PHYLLODES TUMORS: 
 
Table 31: comparison of CD10 expression and tumor grade 
 
Benign(%) Borderline(%) Malignant(%) 
CD10 
+ve 
CD10  
-ve 
CD10 
+ve 
CD10  
-ve 
CD10 
+ve 
CD10  
-ve 
Ibrahim 
WS et 
al[76] 
4 
(16.7%) 
20 
(83.3%) 
3 
(60%) 
2 
(40%) 
4 
(80%) 
1 
(20%) 
Tse GMK 
et al[74] 
6 
(5.9%) 
96 
(94.1%) 
16 
(31.4%) 
35 
(68.6%) 
14 
(50%) 
14 
(50%) 
Masri MA 
et al[77] 
7 
(43.8%) 
9 
(56.3%) 
6 
(60%) 
4 
(40%) 
14 
(82.4%) 
3 
(17.6%) 
Current 
study 
3 
(7.9%) 
35 
(92.1%) 
3 
(50%) 
3 
(50%) 
5 
(83.3%) 
1 
(16.7%) 
 
 According to Ibrahim WS et al[76], most of benign tumor are CD10 
negative with only 16.7% show positivity whereas in borderline 60% show 
CD10 positive remaining 40% show CD10 negative. In case of malignancy 
80% of tumors show CD10 positivity and remaining 20% were negativity 
(Table 31). 
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 CD10 immunoreactivity in benign, borderline and malignant tumors 
were 16.7%, 60% and 80% with P value of 0.0001 showing significant 
correlation between CD10 expression and tumor grade. 
 
 According to Tse GMK et al[74], most of benign tumors show CD10 
negativity accounting for 96.7% with borderline also showing CD10 negativity 
in 68.6% of tumor . In malignant tumors 50% show CD10 postivity and 
remaining 50% tumor show CD10 negativity (Table 31). 
 
 Here CD10 positivity in benign, borderline and malignat were 5.9%, 
31.4% and 50% with p value of <0.001 showing increasing trend of CD10 
expression with increasing grade.  
 
 According to Masri MA et al[77], CD10 positivity in benign , borderline 
and malignant phyllodes tumor were 43.8%,60% and 82.4% respectively with 
p value of 0.02 showing significant correlation. 
 
 In the current study percentage of cases showing CD10 positivity in 
benign, borderline and malignant tumors were 7.9%, 50% and 83.3%. 
Remaining 92.1% of benign tumors were CD10 negative with 50% and 16.7% 
of borderline and malignant tumor were also negative. 
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 When we compare CD10 expression with tumor grade in the current 
study, we get a highly significant P value of 0.000. 
 
 Thus our study also confirms the increase in  CD10 expression with 
increasing grade of phyllodes tumor. 
  
 
 
 
 
Summary 
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SUMMARY 
 
 The percentage of breast specimens among the 28,178 surgical samples 
received at Madras Medical College from January 2012  to june 2014 is 
6.9%. 
 Of this 83 cases were phyllodes tumor accounting for 4.2%. 
 Most common among the cases reported as phyllodes tumor were  
benign tumors constituting 84.3%, followed by malignant and 
borderline constituting 8.4% and 7.2% respectively. 
 All were female patients with no male cases being reported. 
 Phyllodes tumor has peak incidence in the age group of 41 to 50 years 
with mean age of 42.5 years and most cases range in size from 6 to 10 
cm with mean size of 6.6cm. Incidence of malignancy increases with 
increasing age and larger size of the tumor. 
 In benign tumors age group ranges from 17 to 57 years with mean age 
of 39.7 years and size varies from 3cm to 15cm witn mean size of 
5.6cm. 
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 In Borderline tumor age group ranges from 35 to 60 years with mean 
age of 47.8 years and size varies from 5 to 14cm with mean size of 
8.5cm. 
 Among Malignant tumors age group ranges from 51 to 60 years with 
mean age of 54 years and size varies from 7 to 19cm with mean size of 
10.8cm. 
 Statistically significant association was seen between age, sex and tumor 
grade. 
 Right sided tumors are more common than left sided tumors accounting 
for 64%, with one case of benign showing bilateral involvement. 
 Upper outer quadrant was found to be commonly involved. 
 In radioimaging most of phyllodes tumors come under BIRADS score 
IV while most of malignant lesion have BIRADS V. 
 Most common clinical presentation is lump in breast followed by pain. 
 Stromal cellularity, stromal overgrowth, cytological atypia, nature of 
margin and mitotic rate increases with increasing grade. 
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 CD10 intensity of staining is more in malignant lesions with almost all 
cases showing moderate to strong staining, while only 6 cases (15.8%) 
of benign tumors show moderate to strong intensity of stain. 
 Statistically significant association was seen between intensity of 
staining and tumor grade. 
 CD10 expression was seen in 11 cases of phyllodes tumor, out of which 
5 case (83.3%) were malignant, 3 cases (50%) were borderline and 3 
cases(7.9%) were benign tumors.  
 The association between CD10 expression and tumor grade is found to 
be statistically significant. 
 
  
 
 
 
 
Conclusion 
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CONCLUSION 
 
 This is a hospital based study and may not represent the true incidence 
in the community. Phyllodes tumor account for 4.2% of all breast specimens 
received in the institute of pathology from January 2012 to june 2014. Peak 
incidence occurs in the age group of 41 to 50 years. Most common subtype is 
bening tumor. As metastasis and local recurrence are more common in 
malignant tumor this necessitates the use of molecular markers for grading of 
tumor. 
 
 CD10 expression is more in malignant and borderline tumors when 
compared to benign tumors. In this study CD10 expression is significantly 
associated with increasing grade of tumor. This concludes the role of CD10 
expression in grading of tumor.  
 
 A large sample study in future may show the significance of CD10 as a 
prognostic marker and might pave way for developing targeted therapy. 
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Annexures 
 
 
 
ANNEXURE-I 
PROFORMA 
Case number             :                                                  Name      : 
HPE number             :                                                  Age         :  
IP number                 :                                                  Sex         : 
Clinical diagnosis     :  
Complaint                 : 
Radioimaging           : 
Side of breast            : Right/Left 
Specimen                  : Trucut biopsy/Incision biopsy/ 
                                    Lumpectomy/Wide local excision/Mastectomy/others. 
GROSS                     
Specimen size          :                                                     Skin        : 
Tumor size               :                                                    Tumor margin: 
Appearance              : 
Resected margins     :   
(In WLE and mastectomy) 
MICROSCOPY       : Histological diagnosis 
IHC 
CD10                       :        Intensity of staining           : 
                                         Percentage of cells Stained :                                                                
                                         Positive / Negative              :   
 
 
ANNEXURE II 
Mammogram  
              Normal breast appears dark grey to black on mammogram due to 
radioluscent fat which provides excellent background. 
Breast Imaging And Reporting Data System: 
It is modified from American College of radiology. 
Category Assessment Recommendation 
1 Negative  
2 Benign finding  
3 Probably benign finding Short term follow up recommended 
4 Suspicious looking abnormality Biopsy should be considered 
5 Highly suggestive of malignancy Appropriate action to be taken 
6 Known cancer Appropriate action to be taken 
 
  
MASTER CHART 
 
 
KEY TO MASTER CHART 
SIDE: 
       Rt    -   Right 
       Lt    -   Left 
T/L  -  Tumor location 
      AQ    -   All quadrant 
      CQ    -   Central quadrant 
      UOQ -   Upper outer quadrant 
      UIQ  -   Upper inner quadrant 
      LOQ -   Lower outer quadrant 
      C/F   - Clinical features 
      ND    - Nipple discharge 
P/D  - Procedure done 
      IN      -   Incision biopsy 
      TR     -   Trucut biopsy 
      WLE -   Wide local excision 
      SM    -  Simple mastectomy 
      LU    -  Lumpectomy 
G/margin- gross margin 
        0    -   Margin not known 
        1    -   Infiltrative 
        2    -   Pushing 
Cellularity 
       1    -   Minimal 
       2    -   Moderate 
       3    -   Marked 
Atypia 
       0    -   None 
       1    -   Minimal 
       2    -   Moderate 
       3    -   Marked 
O.Growth- Stromal over growth 
       1    -   Minimal 
       2    -   Moderate 
       3    -   Marked 
Mitosis 
       1     -   0-4/Hpf 
       2     -   5-9/Hpf 
       3     -    >10/Hpf 
Margin 
        0    -   Margin not known 
        1    -   Involved 
        2   -    Uninvolved 
Type of  tumor 
       B   -   Benign phyllodes 
       I    -   Intermediate phyllodes  
       M  -   Malignant phyllodes 
CD10 INT-CD10 intensity of stain 
       0    -    No staining 
       1     -   Weak 
       2     -   Moderate 
       3     -    Strong 
% OF CELLS- Percentage of cells taken stain 
0     -   Nil 
1       -   <20%  cells  
2       -   >20% cells 
CD10+/-   -    CD10 positive/Negative 
       N     -   Negative 
       P     -   Positive  
        
